Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189435 | 0.81 | ALDH1A1 (0.42) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL19210151 | 0.80 | KMT2A (0.37) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL14341342 | 0.79 | IDO1 (0.41) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL15259645 | 0.78 | — | — | |
| SCHEMBL13751208 | 0.77 | RECQL (0.36) | SMN1; SMN2ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29138431 | 0.74 | ALDH1A1 (0.39) | KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL29138432 | 0.72 | SLC6A2 (0.38) | KMT2ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL2977303 | 0.72 | HPGD (0.33) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL16967658 | 0.71 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL1188054 | 0.70 | KMT2A (0.37) | KMT2APOLBSMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3205652-B1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| EP-3205652-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2017-08-16 | — | — | EP | disclosed |
| US-9040706-B2 | Pyrrolidine inhibitors of IAP | GENENTECH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8907092-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8835393-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20120270886-A1 | INHIBITORS OF IAP | KOEHLER MICHAEL F T (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120202750-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120015974-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8063218-B2 | Imidazopyridine inhibitors of IAP | GENENTECH, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110269696-A1 | INHIBITORS OF IAPS | GENENTECH INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110218211-A1 | AZAINDOLE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110077265-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110046066-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20100130539-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | GENENTECH INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269696-A1 | INHIBITORS OF IAPS | XIAP, BIRC5, BIRC3 | KMT2A 4292/4885POLB 4233/4885SMN1; SMN2 2051/4885 |
| US-20110046066-A1 | INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | KMT2A 4048/4885POLB 4068/4885SMN1; SMN2 2624/4885 |
| US-20120202750-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC3 | KMT2A 3374/4885POLB 4407/4885SMN1; SMN2 2479/4885 |
| US-20120270886-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC3 | KMT2A 3440/4885POLB 4336/4885SMN1; SMN2 2250/4885 |
| US-20120015974-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | KMT2A 3139/4885POLB 4329/4885SMN1; SMN2 2109/4885 |
| US-20110218211-A1 | AZAINDOLE INHIBITORS OF IAP | XIAP, BIRC5, API5 | KMT2A 2230/4885POLB 4543/4885SMN1; SMN2 2777/4885 |
| US-20100130539-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | KMT2A 3139/4885POLB 4329/4885SMN1; SMN2 2109/4885 |
| US-20140080805-A1 | PYRROLIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC2 | KMT2A 3431/4885POLB 2889/4885SMN1; SMN2 2913/4885 |
| US-20110077265-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC2 | KMT2A 3444/4885POLB 3470/4885SMN1; SMN2 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.